4d Molecular Therapeutics Inc (FDMT) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
4d Molecular Therapeutics Inc   (NASDAQ: FDMT)


4d Molecular Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is 4d Molecular Therapeutics Inc 's ROA in the second quarter of 2026?
4d Molecular Therapeutics Inc recorded a cumulative net loss of $-179 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -34.68%.

However, within the Healthcare sector 463 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3677, from total ROA ranking in the first quarter of 2026 at 4246.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 18.93 % -0.55 % 4.74 % -27.57 % -22.62 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -179 -161 -140 -209 -196
Return On Assets (TTM) -34.68 % -32.55 % -28.3 % -42.81 % -37.08 %
FDMT's Total Ranking # 3677 # 4246 # 3930 # 3891 # 3861
Total Assets (TTM) in million 563 513 567 424 474
Seq. Total Assets Change 9.82 % -9.49 % 33.66 % -10.48 % -8.16 %
Seq. Net Income Change - - - - -

FDMT's 5 Years Annual ROA >> Back to FDMT Management Effectiveness >> Compare FDMT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 53
Sector # 464
Overall # 3709

Return On Assets Statistics
High Average Low
-22.52 %
-31.84 %
-42.39 %
(Jun 30 2024)   (Sep 30 2025)



  News about 4d Molecular Therapeutics Inc Return on Assets ROA

Breaking Barriers and Battling Challenges 4D Molecular Therapeutics Forges Ahead in the World of Gene Therapy

4D Molecular Therapeutics: Advancements, Challenges, and Promising ResultsIn the realm of drug discovery and gene therapy, 4D Molecular Therapeutics (FDMT) has emerged as a key player, continuously pushing the boundaries of innovation. In recent news, several articles shed light on the company s progress, setbacks, and potential growth. This comprehensive article aims to consolidate these reports to provide a holistic view of 4D Molecular Therapeutics journey.Advancements in Gene Therapy:One of the most significant developments for 4D Molecular Therapeutics came through its R100 Vector, which has demonstrated remarkable progress in the quest to bring forth data on DME (diabetic macular edema) by Q4 of 2024. As reported in the article



Financial Statements
4d Molecular Therapeutics Inc 's Assets $ 563 million FDMT's Balance sheet
4d Molecular Therapeutics Inc 's Income $ -73 million Quarterly FDMT's Income Statement
FDMT's Income by Division See FDMT's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 25.33 % 64.12 % 32.04 % -26.63 % 18.03 %
Total Assets in million 678 541 330 250 340
Y / Y Net Income Change - - - - -
Net Income in million -140 -161 -101 -107 -71
Annual Return On Assets -20.66 % -29.73 % -30.59 % -43.05 % -20.96 %

FDMT's 5 Years Annual ROA >> Back to FDMT Management Effectiveness >> Compare FDMT ROA to its Competitors



More Return On Assets Ratios
FDMT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FDMT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FDMT's Competitors
Subscribers only: Roa for 4d Molecular Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for FDMT's Customers

You may also want to know
FDMT's Roi FDMT's Inventory Turnover Ratio FDMT's Growth Rates FDMT's Dividend Comparisons
FDMT's Profitability Ratios FDMT's Asset Turnover Ratio FDMT's Dividend Growth
FDMT's Roe FDMT's Valuation Ratios FDMT's Financial Strength Ratios FDMT's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-03T11:45:51+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.